Abstract
Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma. We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ⩾ 2 × 10(6) CD34+cells/kg, 80% of them at least 5 × 10(6) CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.
Keywords:
CD34+ collection; Diffuse large B-cell lymphoma; Pegfilgrastim; R-ESHAP; Stem cell mobilization.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Autografts
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / administration & dosage*
-
Granulocyte Colony-Stimulating Factor / adverse effects
-
Hematopoietic Stem Cell Mobilization / methods*
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / therapy*
-
Male
-
Methylprednisolone / administration & dosage
-
Methylprednisolone / adverse effects
-
Middle Aged
-
Peripheral Blood Stem Cell Transplantation*
-
Polyethylene Glycols
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / adverse effects
-
Recurrence
-
Retrospective Studies
Substances
-
Recombinant Proteins
-
Cytarabine
-
Granulocyte Colony-Stimulating Factor
-
pegfilgrastim
-
Polyethylene Glycols
-
Etoposide
-
Filgrastim
-
Cisplatin
-
Methylprednisolone